Search Results - "Poplin, E."

Mortality Associated With Irinotecan Plus Bolus Fluorouracil/Leucovorin: Summary Findings of an Independent Panel by ROTHENBERG, Mace L, MEROPOL, Neal J, POPLIN, Elizabeth A, VAN CUTSEM, Eric, WADLER, Scott

“…To review and assign attribution for the causes of early deaths on two National Cancer Institute-sponsored cooperative group studies involving irinotecan and…”
Get full text

Phase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcoma by Mita, M.M., Poplin, E., Britten, C.D., Tap, W.D., Rubin, E.H., Scott, B.B., Berk, L., Rivera, V.M., Loewy, J.W., Dodion, P., Haluska, F., Sarantopoulos, J., Mita, A., Tolcher, A.

“…Ridaforolimus is an inhibitor of mTOR with evidence of antitumor activity in an I.V. formulation. This multicenter, open-label, 3 + 3 design nonrandomized,…”
Get full text

Dosimetric Parameters That Are Associated With Acute Hematologic Toxicity and FDG-PET/CT Changes in Anal Cancer Patients After Chemoradiation by Newman, N.B, Sidhu, M.K, Baby, R, Moss, R.A, Poplin, E, Patel, N.M, Rezac, C, Goyal, S, Becker, M.D, Jabbour, S.K

Get full text

Association Between Neoadjuvant Chemoradiation Therapy and Hematologic Toxicity During Adjuvant Chemotherapy in Rectal Cancer by Newman, N.B, Sidhu, M.K, Baby, R, Moss, R.A, Rezac, C, Poplin, E, Patel, N.M, Jabbour, S.K

Get full text

Dose-painted Intensity Modulated Radiation Therapy May Offer Improved Morbidity as Compared to 3D-CRT by Tunceroglu, A, Park, J, Poppe, M, Balasubramanian, S, Hernandez, D, Poplin, E, Carpizo, D, Gannon, C, Haffty, B.G, Jabbour, S.K

Get full text

Plastic wound protectors do not affect wound infection rates following laparoscopic-assisted colectomy by KERCHER, K. W, NGUYEN, T. H, HAROLD, K. L, POPLIN, M. E, MATTHEWS, B. D, SING, R. F, HENIFORD, B. T

“…Wound protectors are plastic sheaths that can be used to line a wound during surgery. Wound protectors can facilitate retraction of an incision without the…”
Get full text

Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation by ROBERTS, J. D, POPLIN, E. A, TOMBES, M. B, KYLE, B, SPICER, D. V, GRANT, S, SYNOLD, T, MORAN, R

“…Lometrexol [(6R)-5,10-dideaza-5,6,7,8-tetrahydrofolate] is the prototype folate antimetabolite that targets the de novo purine synthesis pathway. Early phase I…”
Get full text

Combined therapies for squamous-cell carcinoma of the esophagus, a Southwest Oncology Group Study (SWOG-8037) by Poplin, E, Fleming, T, Leichman, L, Seydel, H G, Steiger, Z, Taylor, S, Vance, R, Stuckey, W J, Rivkin, S E

“…Conservative treatment of esophageal cancer with radiation therapy has afforded few long-term survivors. In order to improve outcome, patients with…”
Get more information

Phase Ib trial of bryostatin 1 in patients with refractory malignancies by GRANT, S, ROBERTS, J, POPLIN, E, TOMBES, M. B, KYLE, B, WELCH, D, CARR, M, BEAR, H. D

“…A Phase Ib trial of bryostatin 1, a macrocyclic lactone and protein kinase C (PKC) activator, was conducted in patients with refractory nonhematological…”
Get full text

554 POSTER Pharmacokinetic (PK) and pharmacodynamic (PD) results of Phase I studies of IMC-A12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid malignancies by Rothenberg, M.L, Poplin, E, LoRusso, P, Yu, E, Schwartz, J, Fox, F, Mehnert, J, Sandler, A.B, Rowinsky, E, Higano, C.S

Get full text

321 POSTER A phase I trial evaluating pharmacodynamics of deforolimus (AP23573, MK-8669) delivered orally on multiple dosing schedules by Berk, L, Miller, D, Clapham, D, Loewy, J, Mita, M, Britten, C, Poplin, E, Bedrosian, C.L, Clackson, T, Rivera, V.M

Get full text

Difluorodeoxycytidine (dFcD) : gemcitabine : a phase I study by POPLIN, E. A, CORBETT, T, FLAHERTY, L, TARASOFF, P, REDMAN, B. G, VALDIVIESO, M, BAKER, L

“…Difluorodeoxycytidine (dFdC) demonstrated broad spectrum activity in preclinical models. A phase 1 study utilizing twice weekly injections was conducted in 50…”
Get full text

Phase II Trial of Oral Etoposide in Recurrent or Refractory Endometrial Adenocarcinoma: A Southwest Oncology Group Study by Poplin, Elizabeth A., Liu, P.Y., Delmore, James E., Wilczynski, Sharon, Moore, Dennis F., Potkul, Ronald K., Fine, Bruce A., Hannigan, Edward V., Alberts, David S.

“…Oral etoposide has activity in a wide variety of tumors and is well tolerated. Therefore, the efficacy of oral etoposide was assessed as a treatment of…”
Get full text

Vertebral Bone Marrow Irradiation Contributes to Hematologic Toxicity During Chemoradiation Therapy for Esophageal Cancer by Zhang, A., Deek, M.P., Kim, S., Grann, A., Wagman, R.T., Malhotra, U., Poplin, E., August, D., Jabbour, S.K.

Get full text

Evaluation of multimodality treatment of locoregional esophageal carcinoma by Southwest Oncology Group 9060 by Poplin, Elizabeth A., Jacobson, Joth, Herskovic, Arnold, Panella, Timothy J., Valdivieso, Manuel, Hutchins, Laura F., Macdonald, John S.

“…BACKGROUND Continuous infusion 5‐fluorouracil (CI5‐FU) has been utilized concurrently with radiotherapy to improve tumor control. In this pilot trial,…”
Get full text

Phase I clinical trial of pyrazoloacridine NSC366140 (PD115934) by LORUSSO, P, FOSTER, B. J, POPLIN, E, MCCORMICK, J, KRAUT, M, FLAHERTY, L, HEILBRUN, L. K, VALDIVIESO, M, BAKER, L

“…The pyrazoloacridine (PZA) analogue NSC366140 (PD115934) entered clinical trial based on unique preclinical characteristics including solid tumor selectivity…”
Get full text

Chemoradiotherapy of esophageal carcinoma by Poplin, E A, Khanuja, P S, Kraut, M J, Herskovic, A M, Lattin, P B, Cummings, G, Gaspar, L E, Kinzie, J L, Steiger, Z, Vaitkevicius, V K

“…Chemoradiotherapy has demonstrated efficacy in esophageal cancer but rarely is curative. To improve local control and decrease metastases, a 7-month regimen…”
Get more information

Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer by POPLIN, E. A, LORUSSO, P, LOKICH, J. J, GULLO, J. J, LEMING, P. D, SCHULZ, J. J, VEACH, S. R, MCCULLOCH, W, BAKER, L, SCHEIN, P

“…The use of mitomycin for metastatic colorectal cancer has been limited by mitomycin's myelosuppressive potential. The objective of this randomized study was to…”
Get full text

Phase I study of monoclonal antibody-ricin A chain immunoconjugate Xomazyme-791 in patients with metastatic colon cancer by LoRusso, P M, Lomen, P L, Redman, B G, Poplin, E, Bander, J J, Valdivieso, M

“…The immunoconjugate XMMCO-791/RTA consists of ricin A chain bound to a murine monoclonal antibody MoAb 791T. This monoclonal antibody (MoAb) binds to a…”
Get more information

A Phase II Trial of Piroxantrone in Advanced Ovarian Carcinoma after Failure of Platinum-Based Chemotherapy: Southwest Oncology Group Study 8904 by Albain, Kathy S., Liu, P.Y., Hantel, Alexander, Poplin, Elizabeth A., O'Toole, Robert V., Wade, James L., Maddox, Anne-Marie, Alberts, David S.

“…A phase II trial of the new anthrapyrazole piroxantrone was conducted by the Southwest Oncology Group in advanced ovarian carcinoma. The objectives were to…”
Get full text